REGN (Regeneron Pharmaceuticals, Inc.) — AI Stock Research

Research of September 18, 2026 · Healthcare / Pharmaceutical Preparations

TradeFlare's AI research teams rate REGN a BUY. The latest price is $927.89.

The research plan

• Entry: $790.00
• Target: $908.50
• Stop: $671.50
• Time horizon: weeks

The setup suggests a short-term oversold bounce with longer-term fundamental strength.

Why

The setup suggests a short-term oversold bounce with longer-term fundamental strength. Catalysts to watch: Strong revenue growth driven by key products like Dupixent; Upcoming EYLEA HD launch to further bolster sales; Proprietary technology platforms supporting innovation and competitive advantage. Key risks: EYLEA facing biosimilar competition post-exclusivity; Reliance on two distributors for a significant portion of revenue; Potential pipeline execution and clinical trial risks.

What could push REGN higher

• Strong revenue growth driven by key products like Dupixent.
• Upcoming EYLEA HD launch to further bolster sales.
• Proprietary technology platforms supporting innovation and competitive advantage.

Key risks for REGN

• EYLEA facing biosimilar competition post-exclusivity.
• Reliance on two distributors for a significant portion of revenue.
• Potential pipeline execution and clinical trial risks.

What each AI research team found

Fundamental team: Bullish · valuation: fair

Regeneron Pharmaceuticals presents a compelling fundamental picture driven by strong revenue growth, robust profitability, and a significant competitive moat stemming from its innovative technology platforms. While facing some near-term earnings headwinds and competitive pressures on Eylea, the company's diversified pipeline and positive outlook for new launches like EYLEA HD support a bullish stance. The fair...

• Strong revenue growth (16.7% YoY) driven by key products like Dupixent and the upcoming EYLEA HD launch.
• Robust profitability with a net margin of 27.86% and strong free cash flow generation of $3.57B TTM.
• Proprietary technology platforms (VelociSuite, Regeneron Genetics Center) provide a significant competitive moat and drive innovation.

Technical team: Neutral

The analysis indicates a neutral stance due to conflicting signals across different indicators and a lack of strong conviction from volume. While there are some short-term bullish cues and oversold conditions suggesting a potential bounce, the overall trend is sideways with bearish MACD momentum and declining volume. Therefore, a neutral verdict is appropriate, awaiting clearer directional signals.

• The price is consolidating near a support level with short-term bullish momentum from the MA20, suggesting a potential upward move towards the next resistance if it breaks above current consolidation.
• The stock is trading in a sideways range with declining volume, suggesting a lack of clear direction and potential for a short-term move towards the lower support levels.
• The stock is trading near support with mixed signals, leaning neutral to slightly bearish due to MACD, but oversold Stochastic suggests a potential bounce.

Sentiment team: Neutral

Regeneron Pharmaceuticals presents a neutral sentiment profile, with positive commercial and pipeline developments offset by ongoing litigation and recent trial setbacks. While social media sentiment leans positive due to pipeline potential, professional analyst and news sentiment remain balanced, leading to a stable sentiment momentum. The stock's current oversold RSI suggests potential for a bounce, but...

• Regeneron Pharmaceuticals' news sentiment is neutral, balancing positive developments in its product pipeline and analyst upgrades against ongoing lawsuits and mixed short-term trading performance. (Score: 0.0)
• Regeneron Pharmaceuticals (REGN) exhibits a generally positive sentiment driven by strong pipeline catalysts and attractive valuation, though recent securities lawsuits introduce a notable concern. (Score: 0.15)
• Regeneron Pharmaceuticals exhibits a neutral sentiment driven by strong commercial performance and pipeline catalysts, balanced by ongoing litigation and recent trial setbacks in oncology. (Consensus: Neutral)

Risk team: High

Regeneron presents a high-risk profile due to significant product and customer concentration, coupled with execution risks in its pipeline and substantial historical volatility. The potential for biosimilar competition on EYLEA and recent clinical trial setbacks are critical concerns. Given these factors, a small position size with a tight stop-loss is recommended to manage the elevated downside risk.

• Product Concentration & Competition: Heavy dependence on EYLEA and Dupixent, with EYLEA facing biosimilar competition post-exclusivity expiration, significantly impacting future revenue streams.
• Customer Concentration: Reliance on two distributors for approximately 77% of gross product revenue creates substantial vulnerability to disruptions in these key relationships.
• Pipeline Execution & Clinical Trial Risk: Recent clinical trial setbacks and delays in regulatory approvals for new candidates raise concerns about R&D execution and the company's ability to deliver future growth drivers.

REGN at a glance

Market value	$86.9B
Price / earnings	19.4
Revenue growth (year over year)	9.3%
Profit margin	27.9%
Debt / equity	0.06

Every AI call on REGN since July 31, 2026, and what happened next (4 calls) →

Research of September 18, 2026 · AI-generated analysis for educational purposes, can be wrong, not financial advice.